PARSHALL B LYNNE

SEC source: 0001061983-26-000091 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,784

SEC source: 0001073385-26-000004 · primarydocument.xml · derivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2036-06-23

F1 · derivative.exercise_date: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

SEC source: 0001061983-26-000064 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,784

SEC source: 0001061983-26-000057 · form4.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,301

Underlying: Common Stock · 4,301 shares

Expires 2036-05-26

SEC source: 0001061983-26-000057 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,784

SEC source: 0000874015-26-000172 · edgardoc.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,344

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.85 to $77.115 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-26-000172 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,878

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.77 to $76.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0001061983-26-000014 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,933

SEC source: 0000874015-26-000110 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,344

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.585 to $82.97 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0001061983-25-000038 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,933

SEC source: 0000874015-25-000261 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,344

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.265 to $72.06 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000222 · edgardoc.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,344

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.24 to $51.81 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000222 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,594

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.0137 to $50.92 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000176 · edgardoc.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,344

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.56 to $42.83 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000176 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,744

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.5 to $42.36 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000159 · edgardoc.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,220

Underlying: Common Stock · 4,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000159 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,344

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000142 · edgardoc.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,299

Underlying: Common Stock · 5,220 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000142 · edgardoc.xml · derivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,518

Underlying: Common Stock · 11,518 shares

Expires 2035-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

SEC source: 0001562180-25-004908 · primarydocument.xml · derivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-06-16

SEC source: 0001127602-25-014552 · form4.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,880

Underlying: Common Stock · 10,880 shares

Expires 2035-05-13

F2 · kind: Comprised of stock options that will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier to occur of (x) the one-year anniversary of the date of the grant and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors.

SEC source: 0001127602-25-014552 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,933

F1 · kind: Comprised of restricted stock units ("RSUs") that will vest in one installment on the earlier to occur of (x) the one-year anniversary of the grant date and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. RSUs convert to shares of common stock on a 1:1 basis upon vesting.

SEC source: 0001127602-24-023646 · form4.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2030-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant.

SEC source: 0001127602-24-023646 · form4.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,600

SEC source: 0001127602-24-023646 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-022909 · form4.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2030-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant.

SEC source: 0001127602-24-022909 · form4.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,600

SEC source: 0001127602-24-022909 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-022026 · form4.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 5,000 shares

Expires 2030-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant.

SEC source: 0001127602-24-022026 · form4.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,600

SEC source: 0001127602-24-022026 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-021231 · form4.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 5,000 shares

Expires 2030-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant.

SEC source: 0001127602-24-021231 · form4.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,600

SEC source: 0001127602-24-021231 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-020524 · form4.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2029-05-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-020524 · form4.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,600

SEC source: 0001127602-24-020524 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000182 · edgardoc.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,079

Underlying: Common Stock · 4,677 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000182 · edgardoc.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,265

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0001127602-24-019621 · form4.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2029-05-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-019621 · form4.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,600

SEC source: 0001127602-24-019621 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000165 · edgardoc.xml · derivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,756

Underlying: Common Stock · 4,079 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024.

F4 · derivative.expiration_date: Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024.

SEC source: 0000874015-24-000165 · edgardoc.xml · derivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,111

Underlying: Common Stock · 10,111 shares

Expires 2034-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024.

F2 · derivative.expiration_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024.

SEC source: 0001562180-24-005357 · primarydocument.xml · derivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2034-06-25

SEC source: 0001127602-24-018859 · form4.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 5,000 shares

Expires 2029-05-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-018859 · form4.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,600

SEC source: 0001127602-24-018859 · form4.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-017694 · form4.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 5,000 shares

Expires 2029-05-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-017694 · form4.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,600